national
FDA Grants Expedited Approval for Pancreatic Cancer Drug Daraxonrasib
Just the facts
Acting FDA Commissioner Kyle Diamantas confirmed the regulatory approval was finalized more than six months ahead of the agency's target review date. In a 500-patient clinical trial involving advanced pancreatic cancer cases, patients receiving daraxonrasib achieved a median survival period of 13.2 months compared to 6.7 months for those receiving standard chemotherapy. The therapy works by utilizing a molecular mechanism that targets and binds to mutated proteins within the Ras gene family, which fuel tumor growth in over 90 percent of pancreatic cancer cases. Approximately 67,000 people in the United States are diagnosed with pancreatic cancer annually, a condition with an overall five-year survival rate of 13 percent.
Why this is news
The U.S. Food and Drug Administration granted expedited approval for daraxonrasib, an oral daily medication designed to treat metastatic pancreatic cancer. Developed by California-based Revolution Medicines, the drug will be commercialized under the brand name Rasonque.
Sources
This summary is compiled strictly from the original reporting below.